Honasa slips 3% after ₹135 cr Fluence Pharma deal to enter nutraceuticals
Mamaearth parent buys 58% of Fluence Pharma at 3.4x EV/sales, forming Honasa Health to push B2C nutraceuticals via digital channels. Target ₹500 cr revenue in a ₹16,000 cr market; full buyout planned over 5-7 years. Street wary on margin dilution.
Honasa (Mamaearth parent) acquires 58% of nutraceuticals maker Fluence Pharma at ₹135 crore EV, with plan to absorb remainder over 5-7 years. New subsidiary Honasa Health will build B2C nutraceuticals leveraging digital distribution. Stock fell 3% post-announcement.
Why this matters
Extends Honasa's category push beyond Mamaearth personal care into nutraceuticals, a higher-margin but more regulated adjacency, signaling a platform-brand ambition.
Retail-company activity steady at 3,594 signals over the last 90 days.